Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Keros Therapeutics Inc (KROS)

Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,180,896
  • Shares Outstanding, K 40,507
  • Annual Sales, $ 150 K
  • Annual Income, $ -152,990 K
  • EBIT $ -204 M
  • EBITDA $ -203 M
  • 60-Month Beta 1.23
  • Price/Sales 14,523.50
  • Price/Cash Flow N/A
  • Price/Book 3.78

Options Overview Details

View History
  • Implied Volatility 66.02% ( -0.98%)
  • Historical Volatility 44.62%
  • IV Percentile 36%
  • IV Rank 22.97%
  • IV High 117.21% on 12/04/23
  • IV Low 50.76% on 12/15/23
  • Put/Call Vol Ratio 1.00
  • Today's Volume 2
  • Volume Avg (30-Day) 39
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 2,730
  • Open Int (30-Day) 2,406

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.43
  • Number of Estimates 10
  • High Estimate -1.30
  • Low Estimate -1.63
  • Prior Year -1.34
  • Growth Rate Est. (year over year) -6.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.63 +2.29%
on 11/20/24
70.26 -23.37%
on 11/11/24
-6.46 (-10.71%)
since 10/21/24
3-Month
44.45 +21.12%
on 08/23/24
70.26 -23.37%
on 11/11/24
+6.90 (+14.70%)
since 08/21/24
52-Week
27.31 +97.14%
on 12/12/23
73.00 -26.25%
on 02/29/24
+23.00 (+74.58%)
since 11/21/23

Most Recent Stories

More News
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

KROS : 53.84 (-0.55%)
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

KROS : 53.84 (-0.55%)
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition

KROS : 53.84 (-0.55%)
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

KROS : 53.84 (-0.55%)
Why Shares of Keros Therapeutics Jumped This Week

The company appointed a new director and an analyst reiterated his position on the stock.

BIIB : 158.01 (+1.29%)
VIR : 6.95 (+3.12%)
KROS : 53.84 (-0.55%)
Why Shares of Keros Therapeutics Rose 10.2% This Week

A sympathetic reaction to a competitor's drug helped push the clinical-stage pharmaceutical company's shares higher.

MRK : 99.86 (+2.48%)
KROS : 53.84 (-0.55%)
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

KER-050 data from ongoing Phase 2 study in patients with lower risk myelodysplastic syndromes demonstrated meaningful responses across both ring...

KROS : 53.84 (-0.55%)
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions

LEXINGTON, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...

KROS : 53.84 (-0.55%)
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association

Keros Therapeutics will be hosting a conference call and webcast today, June 10, 2022, at 8:00 a.m. Eastern time. LEXINGTON, Mass., June 10, 2022 ...

KROS : 53.84 (-0.55%)
Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

LEXINGTON, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused...

KROS : 53.84 (-0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 57.62
2nd Resistance Point 56.57
1st Resistance Point 55.20
Last Price 53.84
1st Support Level 52.78
2nd Support Level 51.73
3rd Support Level 50.36

See More

52-Week High 73.00
Fibonacci 61.8% 55.55
Last Price 53.84
Fibonacci 50% 50.15
Fibonacci 38.2% 44.76
52-Week Low 27.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar